저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:

저작자표시. 귀하는 원저작자를 표시하여야 합니다.

비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.

변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

 이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다.

Disclaimer
Tumor mesenchymal stem-like cell as a prognostic marker in primary glioblastoma

Seon-Jin Yoon
Department of Medicine
The Graduate School, Yonsei University
Tumor mesenchymal stem-like cell as a prognostic marker in primary glioblastoma

Directed by Professor Jong Hee Chang

The Master's Thesis submitted to the Department of Medicine, the Graduate School of Yonsei University in partial fulfillment of the requirements for the degree of Master of Medical Science

Seon-Jin Yoon

December 2015
This certifies that the Master's Thesis of Seon-Jin Yoon is approved.

------------------------------------
Thesis Supervisor : Jong Hee Chang

------------------------------------
Thesis Committee Member#1 : Seok-Gu Kang

------------------------------------
Thesis Committee Member#2 : Se Hoon Kim

The Graduate School
Yonsei University

December 2015
ACKNOWLEDGEMENTS

This thesis would not have been possible without the help and guidance of many professors, colleagues, and friends.

I am grateful to Jong Hee Chang, the professor and the neurosurgeon of Severance hospital, for his guidance as the thesis supervisor to write an article regarding the prognosis of primary glioblastoma. His good surgical outcome adhering to a strict management of patients should have also contributed to a good result of this study. I am indebted to Seok-Gu Kang, the professor and the neurosurgeon of Severance hospital, for his fascinating ideas and leadership in basic research isolating cells from tumor tissues. I am quite impressed from Se Hoon Kim, the professor and the neuropathologist of Severance hospital, by his thoughtful interpretation of pathologic reports and advices on this research.

Research team, I want to thank Jin-Kyoung Shim, Ju-Hyung Moon, Tae-Hoon Roh, Ji-Hyun Lee, Eui-Hyun Kim, Jong Hee Chang, Sun Ho Kim, Yong-Kil Hong, Su Jae Lee, Yong Min Huh for their concrete efforts to understand glioblastoma.

Neurosurgery department, Yong Gou Park, Sun Ho Kim, Seung Kon Huh, Do Heum Yoon, Jin Woo Chang, Dong Seok Kim, Keung Nyun Kim, Yoon Ha, Jae Whan Lee, Seong Yi, Kyu Won Shim, Won-Seok Chang, Euihyun Kim, Hyun Ho Jung, Dong Ah Shin, Eun Kyung Park, Keun Young Park, and professors at Gangnam severance hospital, Kyu Sung Lee, Yong Eun Cho, Jin Yang Joo, Keun
Su Kim, Young Sul Yoon, Dong Kyu Chin, Sung Uk Kuk, Chang Ki Hong, Jeong Yoon Park, Yong Bae Kim, Joon Ho Chung, Kyung Hyun Kim, Tae Hoon Roh, Ju Hyung Moon, Hun Ho Park, Kyoung Su Sung. Yoon Ha who ignited my motivation to dip into clinical research, Dong A shin who inspired me to learn more about high performance computing for management of patient data.

**Neurosurgery residents.** Deokyoung Kim, Jang Hoon Kim, Tae Hun Moon, Han Joo Lee, Chang Gi Jang, Hyeong Seok Jeon, Dae Hwan Kim, Seong Jun Ryu, Sangman Park. Woo Sung Lee, Hyun-jin Han who worked together all days and nights to manage the soul of human.

I appreciate those who helped me to go further and perform clinical medicine after graduation, Professor Yong Oock Kim, Woo Jin Hyung, Myongsei Sohn, So Yoon Kim, Seong Hye Kim, Jun Soo Shin, Jeong Mo Nam, Jong Wook Won, Hyun Chang Kim.

And patients with glioblatoma who suffered from the disease and made this research available.

Thank you for my father, mother, and my brother Seon Ho Yoon.
# TABLE OF CONTENTS

ABSTRACT ........................................................................................................... 1

I. INTRODUCTION .............................................................................................. 2
II. MATERIALS AND METHODS ........................................................................... 4
  1. Patient information ......................................................................................... 4
  2. Initial treatment ............................................................................................... 5
  3. Isolation of tumor mesenchymal stem-like cell ............................................. 6
  4. Statistical analysis .......................................................................................... 6
III. RESULTS .......................................................................................................... 7
  1. Patient characteristics .................................................................................... 7
  2. Patient survival ............................................................................................... 8
IV. DISCUSSION ...................................................................................................... 12
V. CONCLUSION ..................................................................................................... 14

REFERENCES ....................................................................................................... 15
ABSTRACT (IN KOREAN) ...................................................................................... 19
LIST OF FIGURES

Figure 1. Kaplan-Meier estimates of overall survival in patients positive and negative for tumor mesenchymal stem-like cells ................................................................. 7

LIST OF TABLES

Table 1. Demographic and clinical characteristics of patients with primary glioblastoma ................................................................. 9
Table 2. Molecular marker expression stratified by isolation of tMSLCs................................................................. 10
Table 3. Cox proportional hazard regression model of factors prognostic for overall survival in patients with primary glioblastoma ................................................................. 11
ABSTRACT

Tumor mesenchymal stem-like cell as a prognostic marker in primary glioblastoma

Seon-Jin Yoon

Department of Medicine
The Graduate School, Yonsei University

(Directed by Professor Jong Hee Chang)

The isolation from brain tumors of tumor mesenchymal stem-like cells (tMSLCs) suggests that these cells play a role in creating a microenvironment for tumor initiation and progression. The clinical characteristics of patients with primary glioblastoma (pGBM) positive for tMSLCs have not been determined. This study analyzed samples from 82 patients with pGBM who had undergone tumor removal, pathological diagnosis, and isolation of tMSLC from April 2009 to October 2014. Survival, extent of resection, molecular markers and tMSLC culture results were statistically evaluated. Median overall survival was 18.6 months, 15.0 months in tMSLC-positive and 29.5 months in tMSLC-negative patients (P=0.014). Multivariate cox regression model showed isolation of tMSLC (OR=2.5, 95% CI=1.1~5.6, P=0.021) showed poor outcome while larger extent of resection (OR=0.5, 95% CI=0.2~0.8, P=0.011) have association with better outcome. The presence of tMSLCs isolated from the specimen of pGBM is associated with the survival of patient.

Key words: isolation, primary glioblastoma, prognosis, stroma, tumor mesenchymal stem-like cell
Tumor mesenchymal stem-like cell as a prognostic marker in primary glioblastoma

Seonjin Yoon

Department of Medicine
The Graduate School, Yonsei University

(Directed by Professor Jong Hee Chang)

I. Introduction

Glioblastomas (GBMs) are generated by interactions between cancer stem cells (CSCs) and stroma. The accumulation of molecular errors in CSCs initiates tumorigenesis, and these CSCs aggregate with stromal cells, which synergistically aggravate the disease. Mesenchymal stem-like cells (MSLCs) have been isolated from normal brain and Lang et.al., presented the isolation of mesenchymal stem cells (MSCs) from glioma for the first time. In addition, tumor MSLCs (tMSLCs) have been isolated from several human brain tumors, suggesting that these cells play a role in creating a microenvironment conducive to brain tumor initiation and progression.

GBMs can be grouped into several subtypes, based on molecular markers, gene expression profiles, and chromosomal aberration.
Based on their genetic characteristics, GBMs can be divided into four types, with the mesenchymal type having the poorest prognosis. Several molecular markers have been shown to be related to survival benefits in patients with GBM, including O-6-methylguanine-DNA methyltransferase (MGMT) methylation and the isocitrate dehydrogenase (IDH) 1/2 mutation. The prognostic value of heterozygosity (LOH) at chromosomes 1p and 19q, however, is unclear. Isolation of CSCs from primary GBM (pGBM) samples can also predict the natural course of pGBM. Although tumor stromal cells were found to have a significant impact on patient survival, the clinical significance of isolation of tMSLCs, a type of stromal cells, from pGBM stroma has not been determined.

We hypothesized that the presence of tMSLCs may aggravate the natural course of pGBM. This study therefore assessed whether the presence of tMSLCs in pGBM patients has an effect on patient survival and prognosis.
II. Materials and methods

*Patient information.* A total of 82 patients with pGBM who received standard therapy\(^{32}\) at two institutions (Severance Hospital, Yonsei University College of Medicine, and Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) from April 2009 to October 2014 were included in this study (Table 1). We followed up the cohort from previous report\(^{11}\) and added new additional patients which were not included in that report.\(^{11}\) Approval for harvest and investigation was obtained from the institutional review boards of the two institutions, and all patients provided written informed consent, as specified in the Declaration of Helsinki. Specimens for isolation of tMSLCs were collected in the operating theater from patients undergoing surgery. All surgical specimens were evaluated by two neuropathologists, who diagnosed each patient according to World Health Organization (WHO) classifications.\(^{33}\) Survival, extent of resection, molecular markers, and tMSLC culture results were analyzed statistically. Inclusion criteria were as follows: the first pathologic diagnosis of primary glioblastoma patients with the standard stupp protocol. Radiation dose of 60 Gy fractionated by 30 times. Stupp protocol within 2 weeks after the pathological diagnosis. Patients who expired during the standard treatment. Excluded patients met following criteria: Recurred glioblastoma after previous surgery. Gliosarcoma. Non-standard dose for temozolomide administration. Hypofractionated radiotherapy. Poor hematologic profile that delayed normal course of standard treatment.
**Initial treatment.** All patients underwent surgical resection, aimed at gross total resection of the tumor, followed by concurrent chemotherapy and radiotherapy and adjuvant chemotherapy.\(^{32}\) Gross total tumor resection was defined as macroscopic removal of 100% or above of the tumor mass found on magnetic resonance (MR) T1 enhanced and T2 images.\(^{34,35}\) Patients not suitable for total resection underwent subtotal resection, defined as removal of macroscopic tumor volume ≥90% but <100%, or partial resection, defined as removal of macroscopic tumor volume <90%. The extent of tumor resection was estimated and classified by the neurosurgeons and rechecked by postoperative review of MR imaging (MRI) scans. All patients received postoperative adjuvant radiotherapy with concomitant and adjuvant temozolomide (TMZ), as described previously.\(^{32}\) Each patient was offered standard therapy\(^ {32}\) after pathologic confirmation. The only factors determining the continuation of standard treatment were patient tolerance (general condition, laboratory abnormalities such as hematologic problems), family agreement for the treatment, and patient survival. The correlation between molecular markers (MGMT methylation, p53, 1p LOH, 19q LOH, Ki-67 indexIDH1 mutation) and survival was analyzed statistically. MGMT methylation was assessed by polymerase chain reaction (PCR), and LOH at chromosomes 1p and 19 q by fluorescent in situ hybridization (FISH).
**Isolation of tMSLCs.** tMSLCs with characteristics similar to MSCs have been isolated from brain tumor specimens. Tumor specimens removed surgically were cultured as described and mesenchymal features were assayed, including plastic adhesion, trilineage differentiation, the presence of typical MSC surface markers (Positive for CD 105, CD 90, CD 72 and negative for CD 45, CD 31, and NG2) and non-tumorigenic behavior.

**Statistical Analysis.** The primary outcome measure was median overall survival (OS), defined as the interval from date of surgery confirming the diagnosis of pGBM to the date of last follow-up visit or death. Immunohistochemical analysis of p53 expression was defined as immunopositivity when the area with staining of ≥50% of cancer cells were found. Ki 67 index was defined as immunopositive when the stained area exceeded 10 % or more. Among clinically deemed primary glioblastoma, 5 patients (6%) had mutation on IDH1. They were not excluded from our study for comprehensive evaluation. Because of small number of patients with IDH1 mutation and previous reports about different clinical characteristics, they were not eligible for survival analysis and excluded from multivariate cox regression model. Survival was analyzed by the Kaplan-Meier method and compared by the log-rank test. Demographic characteristics were compared using Fisher’s exact test or t-test. All statistical analyses were performed using SPSS 22 (IBM Korea, Seoul, Korea), with p values less than 0.05 were regarded as statistically significant.
III. Results

Patient characteristics. Of the 82 patients with pGBM, 48 (59%) were positive and 34 (41%) negative for tMSLCs (Table 1), with no group differences in the extent of resection (P=0.471), age (P=0.683), and expression of specific molecular markers (IDH1, P=0.642; MGMT promoter, P=0.653; p53, P=0.522 for positivity P=0.492 for the percentage of immunohistochemistry; EGFR, P=0.161; Ki 67, P=0.739 for the number of immunostaining P=0.057 for the percentage of immunohistochemistry). All of 48 tMSLCs isolated from specimens showed trilineage differentiation, expression of MSC surface markers, and adherence to a plastic plate without gliomagenesis.

Figure 1. Kaplan-Meier estimates of overall survival in patients positive and negative for tMSLCs. (p = 0.014 by the log-rank test).
**Patient survival.** At a medium follow-up of 11.1 months, 38 patients died. The median survival duration of all pGBM patients was 18.6 months, 15.0 months in patients positive of tMSLCs and 29.5 months in patients negative for tMSLCs (P=0.014; Fig.1). The 6, 12, and 24 month actuarial rates were 86%, 60%, and 21% respectively, in patients positive for tMSLCs, and 93%, 79%, and 61%, respectively, in patients negative for tMSLCs. From univariate cox proportional regression, the only factor associated with poor survival was isolation of tMSLCs from the specimen (OR=2.4, 95% CI=1.2–5.1, P=0.017, Table 3). We included extent of resection, codeletion of 1p19q, MGMT methylation, and Ki 67 index to a multivariate cox model with a result that isolation of tMSLCs (OR=2.5, 95% CI=1.1–5.6, P=0.021) was associated with poorer outcome and larger extent of resection had association with better prognosis (OR=0.5, 95% CI=0.2–0.8, P=0.011) while codeletion of 1p19q, MGMT methylation, and Ki 67 index does not differentiate survival of patients.
Table 1. Demographic and clinical characteristics of patients with pGBM

| Characteristics                        | tMSLCs (+) (N=48) | tMSLCs (-) (N=34) | P value |
|----------------------------------------|-------------------|-------------------|---------|
| Age (years)                            |                   |                   | 0.683   |
| Median                                 | 57.5              | 61                |         |
| Range                                  | 28–85             | 24–80             |         |
| Age – no. (%)                          |                   |                   | 0.899   |
| <50 years – no. (%)                    | 9 (19)            | 6 (18)            |         |
| ≥50 years – no. (%)                    | 39 (81)           | 28 (82)           |         |
| Gender                                 |                   |                   | 0.110   |
| Male – no. (%)                         | 33 (69)           | 17 (50)           |         |
| Female – no. (%)                       | 15 (31)           | 17 (50)           |         |
| Median survival (months)               | 15.0              | 29.5              | 0.014   |
| 95% CI                                 | 9.6–20.4          | 11.9–47.1         |         |
| Pathological diagnosis                 | pGBM              | pGBM              |         |
| Treatment                              | OP/Stupp          | OP/Stupp          |         |
| Extent of operation (Patients)         |                   |                   | 0.471   |
| Gross total resection                  | 29 (60)           | 19 (56)           |         |
| Subtotal resection                     | 18 (38)           | 12 (35)           |         |
| Partial resection                      | 1 (2)             | 3 (9)             |         |

Abbreviations: S.D, Standard deviation; IDH, Isocitrate dehydrogenase; LOH, Loss of heterozygosity; OP/Stupp, Operation followed by Stupp’s regimen;
Table 2. Molecular marker expression stratified by isolation of tMSLCs

| Characteristics | tMSLCs (+) | tMSLCs (-) | \( P \) value |
|-----------------|------------|------------|--------------|
| **Molecular markers** | \( N=48 \) | \( N=34 \) | \( N=48 \) | \( N=34 \) |
| **IDH1** | | | 0.642 |
| Wild type – no. (%) | 39 (91) | 26 (96) | | |
| Mutation – no. (%) | 4 (9) | 1 (4) | | |
| Missing data – no. (%) | 5 (10) | 7 (21) | | |
| **1p19q** | | | 0.341 |
| No codeletion – no. (%) | 37 (80) | 30 (91) | | |
| Median survival (months) | 15.0 | 29.5 | 0.011 |
| 95% CI | 8.9–21.1 | 9.1–50.0 | | |
| Codeletion – no. (%) | 9 (20) | 3 (9) | | |
| Median survival (months) | 12.9 | 9.3 | 0.886 |
| 95% CI | 0.8–25.0 | 1.6–17.0 | | |
| Missing data – no. (%) | 2 (4) | 1 (3) | | |
| **MGMT promoter** | | | 0.653 |
| Wild type – no. (%) | 27 (59) | 18 (53) | | |
| Median survival (months) | 15.0 | NA | 0.122 |
| 95% CI | 8.8–21.2 | NA | | |
| Methylated – no. (%) | 19 (41) | 16 (47) | | |
| Median survival (months) | 18.6 | 34.1 | 0.164 |
| 95% CI | 6.2–31.0 | 13.6–54.6 | | |
| Missing data – no. (%) | 2 (4) | 0 (0) | | |
| **p53** | | | 0.522 |
| IHC negative (<50%) – no. (%) | 23 (77) | 13 (65) | | |
| Median survival (months) | 13.7 | NA | 0.324 |
| 95% CI | 9.8–17.6 | NA | | |
| IHC positive (≥50%) – no. (%) | 7 (23) | 7 (35) | | |
| Median survival (months) | 18.6 | NA | 0.704 |
| 95% CI | 9.9–27.3 | NA | | |
| IHC Mean ± S.D. | 28.4±27.0 | 33.9±28.8 | 0.492 |
| Range (%) | 1.5–85 | 2.5–90 | | |
| Missing data – no. (%) | 18 (38) | 14 (41) | | |
| **EGFR** | | | 0.161 |
| IHC Mean ± S.D. | 1.9±1.1 | 2.3±0.9 | | |
| Range | 0–3 | 0–3 | | |
| Missing data – no. (%) | 6 (13) | 7 (21) | | |
| **Ki 67** | | | 0.739 |
| IHC negative (<10%) – no. (%) | 5 (11) | 3 (9) | | |
| IHC positive (≥10%) – no. (%) | 40 (89) | 31 (91) | | |
| IHC % Mean ± S.D. | 22.6±14.1 | 30.1±20.2 | 0.057 |
| Range (%) | 2–60 | 3–80 | | |
| Missing data – no. (%) | 3 (6) | 0 (0) | | |

Abbreviations: S.D, Standard deviation; MGMT, O-6-methylguanine-DNA methyltransferase; EGFR, epidermal growth factor receptor; NA, Not available.
Table 3. Cox proportional hazard regression model of factors prognostic for overall survival in patients with pGBM

| Characteristics                  | Univariate |               |            |            |            |            |            |
|----------------------------------|------------|---------------|------------|------------|------------|------------|------------|
|                                  | OR         | 95% CI        | P value    | OR         | 95% CI        | P value    |
| Isolation of tMSLCs              | 2.4        | 1.2~5.1       | 0.017      | 2.5        | 1.1~5.6       | 0.021      |
| Age ≥ 50 years                   | 1.3        | 0.5~3.1       | 0.587      |            |            |            |
| Extent of resection              | 0.7        | 0.4~1.1       | 0.151      | 0.5        | 0.2~0.8       | 0.011      |
| IDH1 mutation                    | 1.6        | 0.4~6.7       | 0.551      |            |            |            |
| LOH 1p19q                        | 1.3        | 0.6~3.0       | 0.532      | 1.1        | 0.4~2.6       | 0.869      |
| MGMT methylation                 | 0.8        | 0.4~1.6       | 0.522      | 0.9        | 0.4~1.9       | 0.792      |
| p53 ≥ 50%                        | 0.7        | 0.2~1.8       | 0.418      |            |            |            |
| EGFR                             | 1.1        | 0.7~1.5       | 0.782      |            |            |            |
| Ki 67 index ≥ 10%                | 3.3        | 0.5~24.7      | 0.235      | 5.4        | 0.7~42.0      | 0.107      |

Abbreviations: tMSLCs, tumor mesenchymal stem-like cells; IDH, isocitrate dehydrogenase; LOH, loss of heterozygosity; MGMT, O-6-methylguanine-DNA methyltransferase; EGFR, epidermal growth factor receptor; OR, odds ratio; CI, confidence interval
IV. Discussion

MSLCs are cells with MSC-like properties that have been isolated from brain\textsuperscript{6,7}, especially from brain tumors (tMSLCs).\textsuperscript{2,9-11,13,39} These cells possess MSC surface antigens, show trilineage differentiation, adhere to plastic plates, and are non-tumorigenic.\textsuperscript{11,13,36}

This study found that OS differed significantly between pGBM patients positive and negative for tMSLCs, suggesting that tMSLCs may play a role in the progression of pGBM. Although the “seed and soil” concept of cancer biology was proposed more than 125 years ago,\textsuperscript{40-42} GBM tumorspheres (TS) have been demonstrated recently,\textsuperscript{43,44} with tMSLCs being a factor in this concept.\textsuperscript{9-12} Although the exact function of tMSLCs in pGBM is not well understood, this study showed that tMSLCs were clinically important, in that they were prognostic of survival. The next step should be to assess the interactions between the GBM TS and tMSLCs.

Small number of patients (82 cases in total) recruited to this retrospective study is a limitation to interpret the results of this study. Although we compiled as many patients as possible, only subgroup that meets strict inclusion and exclusion criteria has limited number of patients. As our analysis does not show different prognosis in overall survival that was determined by MGMT methylation or LOH of 1p19q which was shown in more inclusive larger patient set, cautious interpretation of our result is required.
From original group of 82 patients, only five of 70 patients tested (7.1%) had IDH1 mutations, including one from 27 tMSLC-negative (3.7%) and four from 43 tMSLC-positive (9.3%) patients. While these 5 tumors were not clinically suspected as secondary glioblastomas, they were excluded from multivariate cox regression model as the entity was shown to have different prognosis.\(^{38}\) Patients with mutated IDH1 were younger than those with wild-type IDH1 (45.3 vs 60.7 years).\(^{38}\) Although LOH at 1p or 19q was found to correlate with longer OS in patients with oligodendroglioma\(^{45}\) the association in patients with pGBM remains unclear. In our result, codeletion of 1p19q was not associated with prognosis (Univariate: OR=1.3, 95% CI=0.6~3.0, P=0.532, Multivariate: OR=1.1, 95% CI=0.4~2.6, P=0.869). Analysis of MGMT promotor showed that 42% of specimens were methylated (41% in tMSLCs(+), 47% in tMSLCs(-)), and that median OS tended to be longer in patients with than without methylation while lacking statistical significance (18.6 vs 15.0 months, P=0.650). IHC analysis of p53 found that 28% of specimens were stained for this marker. However, median OS was similar in p53 positive and negative patients (18.6 vs 13.7 months, P=0.415).

In this study, tMSLCs were isolated from 58.5% of patients with pGBM, compared with 46.2% in a previous study.\(^{11}\) This increase, despite using the same isolation method, reemphasizes that isolation of a specific cell type from a tumor specimen requires a standardized method or may reflect a learning curve among laboratory staffs. Further research may identify specific
cell markers prognostic of OS.

Mesenchymal features may contribute to poor survival in patients with brain tumors. Higher grade gliomas\textsuperscript{11} and meningiomas\textsuperscript{10} are more likely to identified to have tMSLCs. Indeed, tMSLCs could not be isolated from WHO grade 1 gliomas and meningiomas, whereas 20\%, 33\%, and 32\% (or 46.2\% without secondary GBM and recurrent GBM) of WHO grades 2, 3, and 4 gliomas, respectively, were positive for tMSLCs.\textsuperscript{11} It remains unclear, however, whether the presence of tMSLCs aggravates the natural history of a brain tumor or contributes to tumor progression.

V. Conclusions
Isolation of tMSLCs is associated with the survival of pGBM patients. tMSLCs may have a critical role in the survival of patients with pGBM. Other cell types may predict the clinical course of patients with pGBM. In addition, cell surface markers and molecular markers of pGBM may have prognostic value, and the interactions of tMSLCs with gCSCs may better reveal the role of these cell types in pGBM patients.
Reference

1. Dong J, Zhang Q, Huang Q, Chen H, Shen Y, Fei X, et al. Glioma stem cells involved in tumor tissue remodeling in a xenograft model. J Neurosurg 2010;113:249-60.

2. Behnan J, Isakson P, Joel M, Cilio C, Langmoen IA, Vik-Mo EO, et al. Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression. Stem Cells 2014;32:1110-23.

3. Golebiewska A, Bougnaud S, Stieber D, Brons NH, Vallar L, Hertel F, et al. Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. Brain 2013;136:1462-75.

4. Li L, Cole J, Margolin DA. Cancer stem cell and stromal microenvironment. Ochsner J 2013;13:109-18.

5. Mognetti B, La Montagna G, Perrelli MG, Pagliaro P, Penna C. Bone marrow mesenchymal stem cells increase motility of prostate cancer cells via production of stromal cell-derived factor-1alpha. J Cell Mol Med 2013;17:287-92.

6. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006;119:2204-13.

7. Kang SG, Shinojima N, Hossain A, Gumin J, Yong RL, Colman H, et al. Isolation and perivascular localization of mesenchymal stem cells from mouse brain. Neurosurgery 2010;67:711-20.

8. Lang FF, Amano T, Hata N, Gumin J, Aldape K, Colman H. Bone marrow-derived mesenchymal stem cells are recruited to and alter the growth of human gliomas [abstract]. Neuro Oncol 2007;9:596.

9. Kwak J, Shin HJ, Kim SH, Shim JK, Lee JH, Huh YM, et al. Isolation of tumor spheres and mesenchymal stem-like cells from a single primitive neuroectodermal tumor specimen. Childs Nerv Syst 2013;29:2229-39.

10. Lim HY, Kim KM, Kim BK, Shim JK, Lee JH, Huh YM, et al. Isolation of mesenchymal stem-like cells in meningioma specimens. Int J Oncol 2013;43:1260-8.

11. Kim YG, Jeon S, Sin GY, Shim JK, Kim BK, Shin HJ, et al. Existence of glioma stroma mesenchymal stemlike cells in Korean glioma specimens. Childs Nerv Syst 2013;29:549-63.

12. Kong BH, Shin HD, Kim SH, Mok HS, Shim JK, Lee JH, et al. Increased in vivo angiogenic effect of glioma stromal mesenchymal stem-like cells on glioma cancer stem cells from patients with glioblastoma. Int J Oncol 2013;42:1754-62.

13. Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, et al. Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells 2015;33:2400-15.
14. Bourkoula E, Mangoni D, Ius T, Pucer A, Isola M, Musiello D, et al. Glioma-associated stem cells: a novel class of tumor-supporting cells able to predict prognosis of human low-grade gliomas. Stem Cells 2014;32:1239-53.
15. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004;64:6503-10.
16. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 2005;102:5814-9.
17. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
18. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
19. Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015.
20. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007;104:20007-12.
21. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009;4:e7752.
22. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
23. Shen R, Mo Q, Schultz N, Seshan VE, Olshen AB, Huse J, et al. Integrative Subtype Discovery in Glioblastoma Using iCluster. PLoS ONE 2012;7:e35236.
24. Karsy M, Neil JA, Guan J, Mark MA, Colman H, Jensen RL. A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus 2015;38:E4.
25. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of Medicine 2005;352:997-1003.
26. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas. Journal of Clinical Oncology 2009;27:4150-4.
27. Nakamura H, Makino K, Kuratsu J. Molecular and clinical analysis of glioblastoma with an oligodendrogial component (GBMO). Brain Tumor Pathol 2011;28:185-90.
28. Mizoguchi M, Yoshimoto K, Ma X, Guan Y, Hata N, Amano T, et al. Molecular characteristics of glioblastoma with 1p/19q co-deletion. Brain Tumor Pathol 2012;29:148-53.
29. Kong BH, Moon JH, Huh YM, Shim JK, Lee JH, Kim EH, et al. Prognostic value of glioma cancer stem cell isolation in survival of primary glioblastoma patients. Stem Cells Int 2014;2014:838950.
30. Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet 2015;47:312-9.
31. Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 2015;47:320-9.
32. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine 2005;352:987-96.
33. Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A, et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica 2007;114:97-109.
34. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. Journal of Neurosurgery 2008;110:156-62.
35. Kramm CM, Wagner S, Van Gool S, Schmid H, Strater R, Gnekow A, et al. Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. Anticancer Res 2006;26:3773-9.
36. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-7.
37. Mathew A, Pandey M, Murthy NS. Survival analysis: caveats and pitfalls. Eur J Surg Oncol 1999;25:321-9.
38. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clinical Cancer Research 2009;15:6002-7.
39. Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, et al. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res 2006;4:607-19.
40. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;133:571-3.
41. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980;283:139-46.
42. Fidler IJ, Poste G. The "seed and soil" hypothesis revisited. Lancet Oncol 2008;9:808.
43. Kong BH, Park NR, Shim JK, Kim BK, Shin HJ, Lee JH, et al. Isolation of glioma cancer stem cells in relation to histological grades in glioma specimens. Childs Nerv Syst 2013;29:217-29.

44. Sulman E, Aldape K, Colman H. Brain tumor stem cells. Curr Probl Cancer 2008;32:124-42.

45. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004;63:314-22.
일차성 교모세포종 예후 인자인 종양 간엽줄기유사세포 분리

<지도교수 장종희>
연세대학교 대학원 의학과
윤선진

뇌종양에서 간엽줄기유사세포가 분리된다는 것은 종양의 시작과 진행에 영향을 주는 미세환경 조성에 이 세포의 영향이 있음을 시사한다. 그러나 일차성 교모세포종 환자에서 간엽줄기유사세포가 분리된 군의 임상적 특성은 지금까지 보고되지 않았다. 이 논문에서는 2009년 4월부터 2014년 10월까지의 82명 환자에서 얻어진 교모세포종 표본을 분석하였다. 생존, 재발, 종양제거 정도 그리고 분자생물학적 표지자 등이 통계적으로 분석되었다. 중위 생존기간은 18.6개월이었고 간엽줄기유사세포 분리군에서는 생존기간이 15.0개월, 비분리군은 29.5개월이었다 (p=0.014). 다중분석을 통해 본 예후인자는 종양 간엽줄기유사세포 분리 (OR=2.5, 95% CI=1.1~5.6 p=0.021)와 수술의 정도 (OR=0.5, 95% CI=0.2~0.8, p=0.011)가 생존에 영향을 주는 인자들이었다. 일차성 교모세포종에서 종양 간엽줄기유사세포의 분리는 종양의 임상적 진행의 악화 정도와 연관이 있다.

핵심되는 말: 분리, 일차성 교모세포종, 예후, 수술, 종양 간엽줄기유사세포